UNSPSC 51351615: Quinestrol

This classification denotes a steroidal estrogen with the molecular formula C25H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JR0N7XD5GZ, chemically known as 19-norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-(cyclopentyloxy)-, (17.alpha.)- but generally known as quinestrol, which bears US NIH Compound Identifier 1451. European Medicines Agency schedules Quinestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10211MIG.

UNSPSC 51351615 Quinestrol, a Commodity code, encompasses procurement of this specific synthetic progestin pharmaceutical product by state and local government entities, primarily through cooperative purchasing agreements that bundle quinestrol with other generic multi-source pharmaceuticals and over-the-counter products. State and local buyers—including state health departments, correctional facilities, public health agencies, and other government healthcare operations—source quinestrol as part of broader pharmaceutical contracts that consolidate procurement across multiple jurisdictions to achieve volume pricing and supply-chain efficiency. The issuing bodies soliciting under this code include state procurement offices administering multistate cooperative purchasing alliances, individual state agencies, and participating local government entities within those cooperative purchasing vehicles.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and carry specified insurance minimums including $5,000,000 commercial general liability per occurrence. The RFP weights evaluation as follows: price competitiveness (75 percent), fixed pricing (10 percent), compliance with administrative fee data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Awarded vendors will be effective July 1, 2026, with a two-year contract term and optional extensions at MMCAP's discretion.